Compare CHH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | LEGN |
|---|---|---|
| Founded | 1939 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 1997 | 2020 |
| Metric | CHH | LEGN |
|---|---|---|
| Price | $98.39 | $17.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $114.30 | $61.33 |
| AVG Volume (30 Days) | 441.6K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $1,596,793,000.00 | N/A |
| Revenue This Year | $66.74 | $42.68 |
| Revenue Next Year | $0.37 | $30.52 |
| P/E Ratio | $53.39 | ★ N/A |
| Revenue Growth | ★ 0.75 | N/A |
| 52 Week Low | $84.04 | $16.24 |
| 52 Week High | $123.82 | $37.50 |
| Indicator | CHH | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.92 | 31.42 |
| Support Level | $93.51 | $16.47 |
| Resistance Level | $98.71 | $21.99 |
| Average True Range (ATR) | 3.14 | 0.88 |
| MACD | -0.64 | -0.24 |
| Stochastic Oscillator | 10.83 | 3.31 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.